Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Nintedanib Gets FDA Breakthrough Therapy Designation for IPF

July 17, 2014 2:16 pm | News | Comments

Boehringer Ingelheim Pharmaceuticals Inc. announced that the FDA has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under review for the treatment of people with idiopathic pulmonary fibrosis (IPF). Read more...

TOPICS:

FDA Approves Salix-Pharming Angioedema Treatment

July 17, 2014 2:07 pm | News | Comments

Salix Pharmaceuticals Ltd. and Pharming Group NV announced that the FDA has approved Ruconest for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Read more...         

TOPICS:

BMS, Pfizer Launch Phase 4 Eliquis Trial

July 17, 2014 1:54 pm | News | Comments

Bristol-Myers Squibb and Pfizer announced that the first patient has been enrolled into a Phase 4 clinical trial called EMANATE, assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion. Read more...

TOPICS:
Advertisement

Arthritis Drug Shown to Slow Alzheimer’s

July 17, 2014 1:45 pm | News | Comments

A drug that is commonly used for arthritis has been shown to slow the progression of Alzheimer’s. A small randomized control study tested the drug Etanercept on patients with mild to moderate Alzheimer’s. Read more...          

TOPICS:

Protein Injection Halts Diabetes in Mice

July 17, 2014 1:36 pm | Videos | Comments

In mice with diet-induced diabetes—the equivalent of type 2 diabetes in humans—a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days. The discovery could lead to a new generation of diabetes drugs. Read more...

TOPICS:

Biotie Selects CDR System for Parkinson's Trial

July 17, 2014 11:11 am | News | Comments

Bracket is pleased to announce that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected the CDR System for use as the primary endpoint for their Phase 2 trial of SYN120, an orally administered, dual 5HT6/5HT2a antagonist. Read more...

TOPICS:

Wales Kicks Off Hub to Accelerate Growth in Life Sciences

July 17, 2014 11:07 am | News | Comments

The Welsh Government has launched the Life Sciences Hub Wales, which will create a vibrant and prosperous Life Sciences ecosystem bringing together academic, business, clinical, professional services and funding organizations to provide a commercially-driven melting pot of talent. Read more...

TOPICS:

Medicines Patent Pool Speeds Availability of Generic HIV Drugs

July 17, 2014 11:00 am | News | Comments

Three days before the start of the 20th International AIDS Conference in Melbourne, Australia, the Medicines Patent Pool (MPP) announced seven new sub-licensing agreements for the manufacture of generic HIV medicines, atazanavir (ATV) and dolutegravir (DTG). Read more...

TOPICS:
Advertisement

Studies Reveal New Niacin Risks

July 17, 2014 10:54 am | by Marilynn Marchione, AP Chief Medical Writer | News | Comments

New details from two studies reveal more side effects from niacin, a drug that hundreds of thousands of Americans take for cholesterol problems and general heart health. Some prominent doctors say the drug now seems too risky for routine use. Read more...

TOPICS:

Scientists Trap, Kill Malaria Parasite

July 17, 2014 10:45 am | by Michael C. Purdy | News | Comments

Scientists may be able to entomb the malaria parasite, Plasmodium falciparum, in a prison of its own making, researchers at Washington University School of Medicine in St. Louis report in Nature, which in another story highlights the importance of a pore to the parasite’s survival. Read more...

TOPICS:

Reoviruses: The Discovery of Their Potential in Cancer Therapeutics

July 17, 2014 10:23 am | by Brad Thompson, Ph.D., President and Chief Executive Officer of Oncolytics Biotech | Articles | Comments

Reoviruses - first isolated in 1951 - are benign viruses with an important property: they are oncolytic, meaning they are capable of infecting and destroying many kinds of cancer cells. The story of how this discovery was made is an exciting one. Read more...

TOPICS:

FDA Grants QIDP Designation to Astellas Candidiasis Treatment

July 16, 2014 1:35 pm | News | Comments

Astellas announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis. Read more...               

TOPICS:

Isis Earns $1M from GSK for Advancing ISIS-TTR Rx

July 16, 2014 1:21 pm | News | Comments

Isis Pharmaceuticals Inc. announced that it has earned a $1 million milestone payment from GSK, related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. Read more...        

TOPICS:

Pfizer to Acquire InnoPharma for $225M

July 16, 2014 1:07 pm | News | Comments

Pfizer Inc. and InnoPharma Inc., a privately held pharmaceutical development company, announced that they have entered into an agreement under which Pfizer will acquire InnoPharma. Read more...                 

TOPICS:

New Brain Protein Tied to Alzheimer's Disease

July 16, 2014 1:01 pm | by Marilynn Marchione, AP Chief Medical Writer | News | Comments

Scientists have linked a new protein to Alzheimer's disease, which could give a new target for developing drugs and other treatments for Alzheimer's, the most common form of dementia. Read more...                

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading